Item 8.01 Other Events

On January 18, 2023, Catalyst Pharmaceuticals, Inc. (the "Company") received a Paragraph IV Certification Notice Letter (the "Notice Letter") from Teva Pharmaceuticals, Inc. ("Teva") advising that Teva had submitted an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA") seeking authorization from the FDA to manufacture, use or sell a generic version of FIRDAPSE® in the United States.

In the Notice Letter, Teva states that it intends to market a generic version of FIRDAPSE® before the expiration of the Company's patents listed in the FDA Orange Book covering FIRDAPSE®: U.S. Patent Numbers 10,626,088 (expiring February 2037); 10,793,893 (expiring May 2034); 11,060,128 (expiring June 2032); 11,268,128 (expiring June 2032); 11,274,331 (expiring June 2032); and 11,274,332 (expiring June 2032). Teva's Notice Letter states that its ANDA contains a Paragraph IV Certification alleging that these patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use or sale of the proposed product described in Teva's ANDA submission.

Under the Food and Drug Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, after receipt of a valid Paragraph IV notice, the Company may bring a patent infringement suit in a federal district court against Teva within 45 days from the receipt of the Notice Letter. If such a suit is commenced within the 45-day period, the Company is entitled to a 30 month stay on the FDA's ability to give final approval to any proposed products that reference FIRDAPSE®. In the present case, the 30-month stay is expected to preempt any final approval by the FDA on Teva's ANDA until at least May 2026.

The Company is currently assessing the Notice Letter and intends to vigorously defend its intellectual property rights relating to FIRDAPSE®.

On January 23, 2023, the Company issued a press release announcing the receipt of the Notice Letter. The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements relating to, among other things, the Company's intention to vigorously enforce its intellectual property rights. Any such statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "potential," "may," "expects," "intends" and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on the Company's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, those risks and uncertainties relating to the Company's ability to successfully enforce its intellectual property rights and to defend its patents, the possible introduction and timing of generic competition to FIRDAPSE®, and the other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. The Company does not undertake any obligation to update any forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.



                                       2

--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits

(d) Exhibits



99.1      Press release issued by the Company on January 23, 2023

104     Cover Page Interactive Data File (embedded within the inline XBRL document)



                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses